HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

A phase I trial of flavopiridol in relapsed multiple myeloma.

AbstractPURPOSE:
Flavopiridol is primarily a cyclin-dependent kinase-9 inhibitor, and we performed a dose escalation trial to determine the maximum tolerated dose and safety and generate a pharmacokinetic (PK) profile.
METHODS:
Patients with a diagnosis of relapsed myeloma after at least two prior treatments were included. Flavopiridol was administered as a bolus and then continuous infusion weekly for 4 weeks in a 6-week cycle.
RESULTS:
Fifteen patients were treated at three dose levels (30 mg/m(2) bolus, 30 mg/m(2) CIV to 50 mg/m(2) bolus, and 50 mg/m(2) CIV). Cytopenias were significant, and elevated transaminases (grade 4 in 3 patients, grade 3 in 4 patients, and grade 2 in 3 patients) were noted but were transient. Diarrhea (grade 3 in 6 patients and grade 2 in 5 patients) did not lead to hospital admission. There were no confirmed partial responses although one patient with t(4;14) had a decrease in his monoclonal protein >50 % that did not persist. PK properties were similar to prior publications, and immunohistochemical staining for cyclin D1 and phospho-retinoblastoma did not predict response.
CONCLUSIONS:
Flavopiridol as a single agent given by bolus and then infusion caused significant diarrhea, cytopenias, and transaminase elevation but only achieved marginal responses in relapsed myeloma (ClinicalTrials.gov identifier NCT00112723).
AuthorsCraig C Hofmeister, Ming Poi, Mindy A Bowers, Weiqiang Zhao, Mitch A Phelps, Don M Benson, Eric H Kraut, Sherif Farag, Yvonne A Efebera, Jennifer Sexton, Thomas S Lin, Michael Grever, John C Byrd
JournalCancer chemotherapy and pharmacology (Cancer Chemother Pharmacol) Vol. 73 Issue 2 Pg. 249-57 (Feb 2014) ISSN: 1432-0843 [Electronic] Germany
PMID24241210 (Publication Type: Clinical Trial, Phase I, Journal Article, Research Support, N.I.H., Extramural)
Chemical References
  • Antineoplastic Agents
  • Flavonoids
  • Piperidines
  • alvocidib
Topics
  • Aged
  • Aged, 80 and over
  • Antineoplastic Agents (administration & dosage, adverse effects, blood, pharmacokinetics)
  • Dose-Response Relationship, Drug
  • Flavonoids (administration & dosage, adverse effects, blood, pharmacokinetics)
  • Humans
  • Middle Aged
  • Multiple Myeloma (blood, drug therapy, metabolism, pathology)
  • Piperidines (administration & dosage, adverse effects, blood, pharmacokinetics)
  • Recurrence

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!


Choose Username:
Email:
Password:
Verify Password: